Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny
November 11, 2021
CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer
January 31, 2022
November 23, 2021

CureLab Oncology Secures Patent Protection in India

Patent registration in India opens door to commercial agreements in an enormous market with rising incidence of cancer
india

CureLab Oncology has been granted a patent protection in India for anti-cancer application of our lead product, Elenagen™. This brings the total number of countries in which CureLab Oncology has patent protection to over 20 — you can see the complete list here.

Because of its huge population and established biotech expertise, we see enormous potential in the Indian market for CureLab’s therapies. According to INVEST INDIA, India is among the top 12 destinations for biotechnology in the world, with an approximately 3% share of the global biotechnology industry. In aggregate, the biotech sector is a key contributor to India’s vision of reaching a $5 trillion economy by 2024.

The rising incidence of cancer in India is expected to boost the immuno-oncology drugs market expansion across the country. According to the Indian Council of Medical Research (ICMR) – National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The India immuno-oncology drugs market was valued at $172.8 million in 2018 and is expected to experience a CAGR of 13.1% from 2018 through 2026.

Like any promising biotech company, we view a comprehensive, global approach to IP protection as immensely important to our strategic business plan. One reason is that annual industrial biopharmaceutical R&D spending has declined over the past decade, with large pharmaceuticals instead focusing on partnership and acquisition strategies with biotech startups whose technology shows great promise.

As we expand our patent portfolio and geographic operations, we will adapt our IP strategy to maximize the value of the company.

Share

Related posts

November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.